Imugene Ltd (ASX:IMU, OTC:IUGNF)’s Phase 1 CHECKVacc trial in adults with triple negative breast cancer has been detailed in a publication for the American Society of Clinical Oncology’s (ASCO) 2022 Annual Meeting.
The abstract, entitled 'Phase 1 study of intratumoral administration of CF33-HNIS-antiPDL1 in patients with metastatic triple negative breast cancer' discusses the findings the trial has achieved thus far.
Lead author and principal investigator leading the trial is Dr Yuan Yuan MD, PhD of the City of Hope National Medical Center, Duarte California.
About Imugene
Imugene is a clinical-stage immune-oncology company developing a range of new and novel immunotherapies with the aim of activating the immune system of cancer patients to treat and eradicate tumours.
The company’s platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
Imugene’s product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR-Ts for solid tumours.
The company is supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.